The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Surgical outcomes from the Phase III CheckMate 816 trial
Jonathan Spicer, MD, PhD, McGill University, Montreal, Canada, outlines surgical outcomes from CheckMate 816 (NCT02998528), a Phase III study evaluating nivolumab and platinum-doublet chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). In this study, neoadjuvant nivolumab and chemotherapy did not impede feasibility and timing of surgery, nor the extent of completeness of resection when compared to chemotherapy alone. In addition, patients in the experimental arm demonstrated significant improvement in pathological complete response, representing a potential neoadjuvant option for patients with stage IB to IIIA resectable NSCLC. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
